6H90 Stock Chart & Stats
€0.40
<€0.01(0.25%)
At close: 4:00 PM EDT
€0.40
<€0.01(0.25%)
Day’s Range― - ―
52-Week Range€0.34 - €1.02
Previous CloseN/A
Volume31.00K
Average Volume (3M)7.32K
Market Cap
€151.86M
Enterprise Value€287.49
Total Cash (Recent Filing)€39.81M
Total Debt (Recent Filing)€84.51M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 16, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding303,547,420
10 Day Avg. Volume15,230
30 Day Avg. Volume7,320
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.70
Price to Sales (P/S)2.03
P/FCF Ratio-10.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.17Price Target Upside191.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€84.53M
Bulls Say, Bears Say
Bulls Say
Large Platform Scale & Clinical ValidationExtensive data coverage and clinician engagement create durable network effects for AI model performance and clinical credibility. A large, validated dataset (150M records, 770k clinicians) raises switching costs, supports product improvement, and underpins longer‑term adoption and cross‑sell across health systems.
Shift To Enterprise Recurring RevenueMoving the business to larger, enterprise SaaS contracts improves revenue predictability and customer stickiness. Structural migration from short pilots to million‑dollar enterprise deals supports higher gross margins, longer contract lifecycles, and more durable ARR once implementation milestones are completed.
Material H1 Cash & EBITDA ImprovementSharp year‑to‑date EBITDA and cash‑flow improvement indicates operational leverage and better working capital control. Sustained positive operating cash flow would reduce reliance on external funding and support reinvestment for scaling enterprise deployments and R&D over the medium term.
Bears Say
TTM Negative Cash GenerationPersistent negative operating and free cash flow in the trailing twelve months threatens self‑funding of growth and increases dependence on financing or equity issuance. If enterprise revenue realization lags, continued cash burn could constrain strategic investments and limit runway for integration work.
Profitability Remains NegativeA sustained negative net margin and negative ROE indicate the company has not yet converted revenue scale into durable profitability. Even with margin improvements, prolonged losses can erode capital and reduce flexibility to execute long‑term enterprise strategies without external funding.
Longer Enterprise Sales Cycles & Timing RiskExtended 6–9 month sales cycles make revenue conversion slower and increase forecasting and cash‑flow variability. This structural timing risk delays realization of AI/Data Science growth and may amplify working‑capital needs and execution risk during the multi‑quarter transition to enterprise contracts.
HEALWELL AI News
6H90 FAQ
What was HEALWELL AI’s price range in the past 12 months?
HEALWELL AI lowest stock price was €0.34 and its highest was €1.02 in the past 12 months.
What is HEALWELL AI’s market cap?
HEALWELL AI’s market cap is €151.86M.
When is HEALWELL AI’s upcoming earnings report date?
HEALWELL AI’s upcoming earnings report date is Nov 16, 2026 which is in 95 days.
How were HEALWELL AI’s earnings last quarter?
HEALWELL AI released its earnings results on Aug 07, 2026. The company reported €0.012 earnings per share for the quarter, beating the consensus estimate of -€0.016 by €0.028.
Is HEALWELL AI overvalued?
According to Wall Street analysts HEALWELL AI’s price is currently Undervalued.
Does HEALWELL AI pay dividends?
HEALWELL AI does not currently pay dividends.
What is HEALWELL AI’s EPS estimate?
HEALWELL AI’s EPS estimate is -0.02.
How many shares outstanding does HEALWELL AI have?
HEALWELL AI has 303,547,420 shares outstanding.
What happened to HEALWELL AI’s price movement after its last earnings report?
HEALWELL AI reported an EPS of €0.012 in its last earnings report, beating expectations of -€0.016. Following the earnings report the stock price went up 6.5%.
Which hedge fund is a major shareholder of HEALWELL AI?
Currently, no hedge funds are holding shares in DE:6H90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HEALWELL AI Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€1.17 (191.39% Upside)
€1.17 (191.39% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.58%
Trailing 12-Months
Company Description
HEALWELL AI
Healwell AI Inc., a Toronto-based healthcare technology firm established in 2012, specializes in leveraging artificial intelligence and data science to advance preventative medical care. The company develops an AI-powered platform designed to assist healthcare providers with crucial decision-making. They maintain a significant strategic partnership with WELL Health Technologies Corp., focusing on accelerating the expansion and innovation of AI-driven healthcare solutions. Prior to its current name, adopted in October 2023, the organization was known as MCI Onehealth Technologies Inc.
6H90 Stock 12 Month Forecast
Average Price Target
€1.17
▲(191.39% Upside)
Technical Analysis
Cardiocomm Solutions
―
Reliq Health Technologies
―
Leveljump Healthcare Corp.
―
Kovo HealthTech Corporation
―
Hydreight Technologies Inc
―